Upacicalcet Meets Primary Endpoints in Two Phase 3 Trials for Secondary Hyperparathyroidism

Pathalys Pharma says its investigational calcimimetic upacicalcet met the primary and prespecified secondary endpoints in two pivotal Phase 3 studies, PATH-1 and PATH-2, in hemodialysis patients with secondary hyperparathyroidism (SHPT). The data were presented at ASN Kidney Week 2026 in Denver and simultaneously published in the Journal of the American Society of Nephrology.
- Upacicalcet met the primary endpoint of at least 30% iPTH reduction versus placebo in both PATH-1 and PATH-2, according to Pathalys.
- In PATH-1, 42.1% of upacicalcet patients reached the endpoint versus 16.8% on placebo; in PATH-2 it was 43.5% versus 17.4%.
- Asymptomatic hypocalcemia was the most frequent adverse event: 23% vs. 8% in PATH-1 and 19% vs. 11% in PATH-2.
- Results were presented at ASN Kidney Week 2026 and published in JASN; upacicalcet is not yet FDA approved.
Primary endpoint results
According to Pathalys, upacicalcet met the primary endpoint in both trials: the proportion of participants achieving a reduction of at least 30% in intact parathyroid hormone (iPTH) compared with placebo during the efficacy assessment period, which covered Weeks 22 to 27.
In PATH-1, 42.1% of participants on upacicalcet (101 of 239) reached that threshold, against 16.8% on placebo (20 of 120). In PATH-2, the figures were 43.5% (118 of 271) versus 17.4% (24 of 138).
The company said the trials estimated the effect of upacicalcet under a controlled background-treatment protocol that limited changes in supplemental calcium and active vitamin D sterols, consistent with the 2017 KDIGO guideline update.
Secondary endpoints and safety
Upacicalcet also met two prespecified secondary endpoints. The share of participants with an iPTH reduction of at least 50% was 27.2% versus 7.5% for placebo in PATH-1, and 25.1% versus 4.3% in PATH-2. The share reaching an iPTH of 150 to 300 pg/mL, the target range set by the National Kidney Foundation's K/DOQI, was 18.8% versus 8.3% in PATH-1 and 17.3% versus 4.3% in PATH-2.
Pathalys said upacicalcet was generally well tolerated in both studies. Serious adverse events and gastrointestinal adverse events, most commonly diarrhea and nausea, occurred at similar rates to placebo. The most frequent adverse event was asymptomatic hypocalcemia: 23% with upacicalcet versus 8% with placebo in PATH-1, and 19% versus 11% in PATH-2. Symptomatic hypocalcemia occurred in 0.8% (2 of 239) of upacicalcet participants in PATH-1 and 2% (6 of 271) in PATH-2, versus 0.0% for placebo in both.
In a separate poster, the company reported that biomarker data suggested improvements across the CKD-MBD (chronic kidney disease, mineral and bone disorder) profile. These included reductions in iPTH and whole PTH, reductions in C-terminal and intact FGF23, described as a risk marker for cardiovascular events and mortality in this population, and three markers of bone turnover.
Trial design and the drug
PATH-1 (NCT05832931) and PATH-2 (NCT05836220) were identical, randomized, double-blind, placebo-controlled studies of intravenous upacicalcet (PLS240). They enrolled 359 and 409 participants respectively, randomized 2:1 to upacicalcet or placebo after each hemodialysis session for 27 weeks.
Dosing in the upacicalcet arm started at 25 or 50 mcg depending on corrected serum calcium. Doses could rise every three weeks through Week 19, stepping up to as much as 300 mcg, if corrected calcium was at least 8.3 mg/dL and PTH above 300 pg/mL. Participants then stayed on a stable dose for Weeks 20 to 27. Afterwards, all participants could join an open-label extension receiving upacicalcet three times per week for a maximum of 26 weeks.
Pathalys describes upacicalcet as a small molecule calcimimetic that acts as a positive allosteric modulator. It is thought to activate the calcium-sensing receptor (CaSR) in the presence of extracellular calcium, with little agonist activity when calcium falls below the physiologic range.
What it means for patients and the field
Upacicalcet is investigational and has not been approved by the U.S. Food and Drug Administration. The source does not give a filing or approval timeline.
Jessica Kendrick, MD, MPH, of the University of Colorado Anschutz and primary investigator of the studies, said persistent PTH elevations may contribute to fractures, vascular calcification and cardiovascular disease, and that "there remains a need for new treatment options." Pathalys Chief Medical Officer Bastian Dehmel, MD, said nearly half a million people in the United States receive hemodialysis and that SHPT affects nearly all patients with kidney failure on maintenance dialysis. The company puts the number of U.S. hemodialysis patients at approximately 486,000.
Pathalys, a private company founded in 2021, lists SHPT as the initial focus of its work on chronic kidney disease.

